DINGDANG HEALTH TECHNOLOGY GROUP LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.15 HKD | +5.50% |
|
+12.75% | -42.21% |
| 01/04 | Dingdang Health Technology Slashes Losses in 2023 | MT |
| 28/03 | Dingdang Health Technology Group Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 5.43B 749M 5.87B 62.47B | Sales 2025 * | 6.03B 832M 6.51B 69.34B | Capitalization | 1.43B 197M 1.54B 16.43B |
|---|---|---|---|---|---|
| Net income 2024 * | -92M -12.7M -99.39M -1.06B | Net income 2025 * | -10M -1.38M -10.8M -115M | EV / Sales 2024 * | 0.26 x |
| Net cash position 2024 * | - 0 0 0 | Net cash position 2025 * | - 0 0 0 | EV / Sales 2025 * | 0.24 x |
| P/E ratio 2024 * |
-15.2
x | P/E ratio 2025 * |
-106
x | Employees | 2,615 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 51.16% |
More Fundamentals
* Assessed data
More news
| 1 day | +5.50% | ||
| 1 week | +12.75% | ||
| 1 month | -0.86% | ||
| 3 months | -34.66% | ||
| 6 months | -38.17% | ||
| Current year | -42.21% |
1 week
0.98
1.15
1 month
0.981.21
Current year
0.982.08
1 year
0.983.27
3 years
0.9820.20
5 years
0.9820.20
10 years
0.9820.20
| Managers | Title | Age | Since |
|---|---|---|---|
Wen Long Yang
FOU | Founder | 62 | 20/14/20 |
Yiu Por Lam
DFI | Director of Finance/CFO | 47 | 15/21/15 |
Qing Long Yu
CTO | Chief Tech/Sci/R&D Officer | 39 | 01/15/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wen Long Yang
FOU | Founder | 62 | 20/14/20 |
Li Cai
BRD | Director/Board Member | 40 | 26/21/26 |
Yi Bin Yang
BRD | Director/Board Member | 36 | 25/23/25 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 1.15 | +5.50% | 1,833,500 |
| 25/24/25 | 1.09 | 0.00% | 975,500 |
| 24/24/24 | 1.09 | +5.83% | 1,540,500 |
| 23/24/23 | 1.03 | +1.98% | 562,000 |
| 22/24/22 | 1.01 | -0.98% | 812,000 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 01:38 pm IST
More quotes
Dingdang Health Technology Group Ltd is a China based company mainly engaged in the business of pharmaceutical retail and medical consultation. The Company operates two segments. The Pharmaceutical and Healthcare Business segment is engaged in online direct sales, business distribution, offline smart pharmacies, express delivery services, and online medical consultation. The Others segment provides marketing services, marketplace services and other services. The Company mainly conducts businesses within the domestic market.
Sector
Drug Retailers
Calendar
20/09/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.065
CNY
Average target price
1.366
CNY
Spread / Average Target
+28.32%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -42.21% | 197M | |
| -31.97% | 10.84B | |
| +8.14% | 6.04B | |
| -11.41% | 5.86B | |
| -30.42% | 6.06B | |
| -0.88% | 4.71B | |
| +52.19% | 4.29B | |
| -12.31% | 3.61B | |
| -14.86% | 3.33B | |
| -6.93% | 3.01B |
- Stock Market
- Equities
- 9886 Stock
